Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,460.00    44.00 (3.11%)
Bid:
1,453.00
Ask:
1,454.00
Spread: 1.00 (0.069%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Blocklisting Interim Review

6 Oct 2014 15:58

RNS Number : 5739T
Hikma Pharmaceuticals Plc
06 October 2014
 



 

Block Listing Six Monthly Return

 

Information provided on this form must be typed or printed electronically and provided to an RIS.

 

Date: 6 October 2014

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

&

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

&

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")

Period of return

From:

1 April 2014

To:

30 September 2014

Balance of unallotted securities under scheme(s) from previous return:

SOP: 967,900 ordinary shares of 10 pence

LTIP: 400,050 ordinary shares of 10 pence

MIP: 378,360 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 38,200 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 356,752 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 929,700 ordinary shares of 10 pence

LTIP: 400,050 ordinary shares of 10 pence

MIP: 21,608 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

 

 

 

 

Stock Option Plan ("SOP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

967,900

Blocklisting return 01/04/2014

10/04/2014

0

8,500

959,400

25/04/2014

0

2,500

956,900

23/05/2014

0

1,000

955,900

12/06/2014

0

2,500

953,400

12/06/2014

0

1,700

951,700

21/08/2014

0

6,000

945,700

21/08/2014

0

7,500

938,200

12/09/2014

0

8,500

929,700

Blocklisting return 30/09/2014

 

Long Term Incentive Plan ("LTIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

400,050

Blocklisting return 01/04/2014

30/09/2014

-

-

400,050

Blocklisting return 01/10/2014

 

 

Management Incentive Plan ("MIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

378,360

Blocklisting return 01/04/14

18/05/2014

0

261,480

116,880

12/06/2014

0

11,619

105,261

13/06/2014

0

77,487

27,774

30/06/2014

0

741

27,033

07/08/2014

0

2,856

24,177

22/08/2014

0

794

23,383

04/09/2014

0

300

23,083

12/09/2014

0

1,475

21,608

 Blocklisting return 01/10/14

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRKMMGGDVVGDZM
Date   Source Headline
1st Oct 202511:45 amRNSBlock listing Interim Review
23rd Sep 20251:52 pmRNSDirector/PDMR Shareholding
17th Sep 20259:16 amRNSDirector/PDMR Shareholding
22nd Aug 202512:02 pmRNSDirector/PDMR Shareholding
13th Aug 20251:51 pmRNSDirector/PDMR Shareholding
8th Aug 202512:59 pmRNSDirector/PDMR Shareholding
7th Aug 20257:00 amRNSHalf-year Report
9th Jul 20259:00 amRNSNotice of Results
7th Jul 20259:16 amRNSPublication of Offering Circular
9th Jun 20253:33 pmRNSDirector/PDMR Shareholding
5th Jun 20252:05 pmRNSDirector/PDMR Shareholding
3rd Jun 20251:02 pmRNSDirector/PDMR Shareholding
29th May 20257:00 amRNSFitch upgrades Hikma to ‘BBB’
20th May 20252:49 pmRNSDirector/PDMR Shareholding
15th May 202512:00 pmRNSMedium-term Group guidance ahead of US site visit
8th May 20254:35 pmRNSDirector/PDMR Shareholding
8th May 202510:48 amRNSS&P upgrades Hikma to ‘BBB’
8th May 20258:21 amRNSSettlement agreement for Xyrem® US lawsuits
30th Apr 20251:21 pmRNSDirector/PDMR Shareholding
24th Apr 20253:55 pmRNSResult of AGM
24th Apr 20257:00 amRNSTrading Statement
10th Apr 20252:36 pmRNSDirector/PDMR Shareholding
8th Apr 20251:47 pmRNSDirector/PDMR Shareholding
1st Apr 20259:30 amRNSBlock listing Interim Review
19th Mar 202510:10 amRNSAnnual Financial Report and Notice of AGM
4th Mar 202511:16 amRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNSFinal Results
10th Feb 20258:09 amRNSNotice of Results
23rd Dec 20249:46 amRNSDirector/PDMR Shareholding
7th Nov 20243:30 pmRNSOutcome of Audit Tender Process
7th Nov 20247:00 amRNSTrading Statement
24th Oct 20247:00 amRNS2024 Annual General Meeting Update Statement
1st Oct 20249:45 amRNSBlock listing Interim Review
24th Sep 202410:09 amRNSDirector/PDMR Shareholding
10th Sep 20247:00 amRNSHikma completes Xellia acquisition
13th Aug 20249:39 amRNSDirector/PDMR Shareholding
8th Aug 20247:00 amRNSHalf-year Report
29th Jul 20244:08 pmRNSDirector Declaration
15th Jul 20247:00 amRNSNotice of Results
1st Jul 20242:47 pmRNSTotal Voting Rights
27th Jun 20241:47 pmRNSDirector Declaration
17th Jun 20247:00 amRNSHikma acquires Xellia’s assets
5th Jun 20242:53 pmRNSDirector/PDMR Shareholding
9th May 20249:49 amRNSDirector/PDMR Shareholding
25th Apr 20242:28 pmRNSResult of AGM
25th Apr 20247:00 amRNSTrading Statement
17th Apr 202410:42 amRNSDirector/PDMR Shareholding
15th Apr 20244:43 pmRNSHikma appoints new President of Generics business
11th Apr 202410:58 amRNSDirector/PDMR Shareholding
2nd Apr 20249:50 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.